Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Susan P. Duke"'
Publikováno v:
Therapeutic Innovation & Regulatory Science. 53:293-300
The Biopharmaceutical Section of the American Statistical Association (ASA) formed a Safety Monitoring Working Group to strengthen collaborations between biostatisticians and safety scientists. The task began by surveying current needs and practices
Autor:
Susan P. Duke, Eric Lewis, Deanna D. Hill, Dimitri Bennett, Christi S. Kleoudis, Margaret Polinkovsky
Publikováno v:
Pharmaceutical Medicine. 31:113-118
Rare but serious adverse events are often reasons for the modification of drug product labelling, termination of further development and even withdrawal of a treatment from the market. Our objective was to use analytical methods to evaluate adverse e
Autor:
Amit Bhattacharyya, Mengchun Li, Susan P. Duke, Jonathan Seltzer, Faiz Ahmad, Greg Ball, Lothar Tremmel, Judith Weigel, James M. Buchanan, Qi Jiang, William Wang, Esteban Herrero-Martinez, Wenquan Wang, Raffael Kurek, Barbara A Hendrickson, Dennis O’Brien
Publikováno v:
Therapeutic Innovation & Regulatory Science
Notwithstanding successful harmonization efforts, the global regulatory framework governing product safety is complex and continually evolving, as evidenced by additional regional guidance and regulations. In this regulatory review, we provide an ove
Publikováno v:
Drug Information Journal. 44:29-42
A structured statistical computing environment (SCE) enhances rigor in operational implementation of statistical analyses of clinical studies through process transparency, allowing reproducibility of results by independent reviewers. Desirable featur
Autor:
Scott Osur, Stuart M. Harding, Kenneth G. Faulkner, Susan P. Duke, James P. Kemp, Courtney Crim, Nancy Herje, Stephen Shrewsbury
Publikováno v:
Mayo Clinic Proceedings. 79:458-466
Objective To evaluate the effects of treatment with fluticasone propionate vs placebo on bone, hypothalamic-pituitary-adrenal (HPA) axis function, and the eyes in patients with asthma. Patients and Methods This randomized, double-blind, placebo-contr
Autor:
Jeffery Adelglass, Patrick D. Wire, Richard ZuWallack, Dennis P. Clifford, Stuart M. Harding, Melissa A. Faris, Susan P. Duke
Publikováno v:
Chest. 118:303-312
Objective To evaluate the efficacy and safety of fluticasone propionate administered as a once-daily or twice-daily regimen over a period of 1 year to patients with moderate asthma. Design Double-blind, randomized, parallel group, and placebo-control
Publikováno v:
Drug Information Journal. 34:397-409
Assessment of child growth is problematic: growth is nonlinear in the long-term, and unpredictable in the short-term; growth is subject to a number of environmental as well as genetic influences; and growth is difficult to measure reliably. The poten
Autor:
Vladimir W. Spolsky, R. Lamont MacNeil, Frank J. Raab, Lonnie R. Johnson, Donald H. Newell, Steven Garrett, Charles Q. Harrold, Bradley Beiswanger, Norman H. Stoller, Lawrence E. Wolinsky, William W. Hallmon, Bryan Fitzgerald, Hom-Lay Wang, James T. Mellonig, David F. Atack, Alan M. Polson, G. Lee Southard, Margaret Hill, Ralph M. Arnold, William J. Killoy, Anne P. Polson, Kevin J. Donly, Donald F. Adams, Gerald H. Evans, Philip J. Hanes, Hisham F. Nasi, Mark I. Ryder, Susan P. Duke, Gary Bogle, E. Brady Hancock, Connie Hastings Drisko, Robert Kiger, Carl L. Bandt, R.L. Isaacs, Charles E. Hawley, Simon R. MacNeill
Publikováno v:
Journal of Periodontology. 70:490-503
The clinical efficacy and safety of doxycycline hyclate (8.5% w/w) delivered subgingivally in a biodegradable polymer (DH) was compared to placebo control (VC), oral hygiene (OH), and scaling and root planing (SRP) in 2 multi-center studies.Each stud
Autor:
Steven Garrett, Susan P. Duke
Publikováno v:
Journal of Periodontology. 69:650-654
There has been a tendency by clinicians in periodontal research to confuse lack of significance in a clinical trial designed for superiority for equivalence between the treatment arms. This paper is intended to define for the clinician what equivalen
Publikováno v:
Drug Information Journal. 31:903-909
A trinomial distribution probability model was used to determine the rejection probabilities of various proposed tier-testing schemes for drug content uniformity testing of a unique drug product. The use of this probability model helped in defining a